Context Lung cancer is associated with significant distress, poor quality of life, and a median prognosis of less than one year. Benefits of shared decision making (SDM) have been described for multiple diseases, either by the use of decisions aids or as part of supportive care interventions.
Introduction
Lung cancer represents 13% of all cancer diagnoses and remains one of the most frequently diagnosed cancers worldwide. It is the leading cause of cancer deaths with a median prognosis of less than one year. 1 Patients with lung cancer experience high levels of distress throughout and after treatment, especially when compared to patients with other types of cancer. 2, 3 Also, the overuse of aggressive therapies (e.g. chemotherapy) near the end of life is increasingly regarded as disadvantageous. [4] [5] [6] [7] Patient-centred conversations earlier in the disease course may lead to improved emotional well-being and to care that is aligned with patients' personal preferences. 8, 9 To better achieve such conversations, especially when patients are faced with difficult treatment trade-offs, an increased emphasis is put on the concept of shared decision making (SDM). 10, 11 Especially in preference-sensitive decisions, such as the decision on whether or not to pursue a new course of treatment when faced with a life-limiting illness, SDM is of critical relevance. 10, [12] [13] [14] [15] To date however, patient values and personal preferences are not routinely integrated in clinical care mainly due to time constraints, unawareness, or uncertainty on part of the clinician. 13, 16, 17 In contrast to this, a majority of patients do express a desire to have a role in SDM, emphasizing the need to further develop evidence on how to facilitate such a process. [18] [19] [20] [21] [22] [23] Facilitation of SDM has been shown to improve a patients' emotional state of well-being, increase patient or caregiver involvement, increase decision satisfaction, and possibly reduce overly aggressive therapies near the end of life. 24, 25 In other settings, tools have been developed to specifically facilitate SDM in clinical practice. 26, 27 Such tools, hereafter referred to as decision aids, usually inform patients about benefits and disadvantages of different (treatment) alternatives. To date however, no study has summarized the effects of SDM in patients with lung cancer. We therefore conducted a systematic review to summarize the 
Methods

Design and data sources
The review protocol was registered in PROSPERO (CRD42015026954). We systematically searched the CINAHL, Cochrane, EMBASE, MEDLINE, and PsychINFO databases. Two search updates were performed; the latest update was conducted on 2 May 2018. Terms used in our electronic search strategy were shared decision-making, lung cancer, distress and healthcare utilization. We decided to use a broad search strategy since no MESH heading for "shared decision making" is available. This search strategy included both subject headings and free text terms and was adjusted for the use of synonyms and alternative spellings (Supplement A). A librarian assisted this process. All references were exported to RefWorks, ProQuest LCC, 2017 and duplicates were removed. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist throughout the reporting of our study. 28
Eligible studies
Two investigators (MES and OPG) independently performed an initial screening based on title and abstract. The same investigators performed a full-text appraisal of the remaining studies to determine final inclusion. Reference lists of all included studies were hand searched for additional studies. Disagreements were resolved through a consensus discussion with a third independent investigator (AJB). Studies were eligible for inclusion if all of the following criteria were met:
1) The study contained original data;
2) The study included ≥100 patients with a confirmed diagnosis of lung cancer; authors of studies which included a sample of different cancer populations without reporting M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 separately on the subsample of lung cancer patients were approached for data on the lung cancer patients;
3) The study explicitly detailed on the facilitation of SDM, either as part of a supportive care intervention or by use of a decision aid; 4) SDM had to be facilitated throughout treatment-related decisions: studies reporting on decision rules for clinicians, decisions on lifestyle changes only, clinical trial entry, or education programs not geared towards a specific decision were excluded;
5) The study had a control group in which patients received usual care, we accepted both randomized and non-randomized studies; 6) At least one outcome measure of distress and/or healthcare utilization was used.
We used the definition as provided by Towle et al. 11 to delineate SDM: A process to make decisions that are shared by both doctor and patient by informing patients using best evidence about risks and benefits including patient-specific characteristics and values.
Distress was defined as: "emotional and/or physical distress measured by a generic distress scale and/or a scale measuring symptoms of depression or anxiety". 29 Questionnaires measuring distress were considered to quantify generic distress if two or more of the following domains were covered: physical problems, spiritual problems, social problems, or symptoms of anxiety or depression. We defined healthcare utilization as "any measure quantifying the amount of care a patient may have received" (e.g. the number of hospitalizations throughout the study period or whether a patient received chemotherapy in the last 30 days of life). The time period as defined by the study was used. Since healthcare utilization may be expressed in many different ways, we decided to summarize the effects on the three most frequently used outcomes of healthcare utilization 
Data extraction and statistical analysis
A standardized data extraction form following the CONSORT criteria 30,31 was developed to synthesize the data of selected studies. The extraction form consisted of nine items assessing study methodology (e.g. study design and the follow-up period) and six items evaluating the study's results (e.g. flow of participants throughout the study and numbers of participants analyzed). Whenever multiple measures of one outcome (e.g. different questionnaires to quantify distress) were used, we extracted data from all measures. Different publications detailing on the same study population were analyzed as one study. We expected that pooling of results in a meta-analysis would not be feasible due to intervention-and outcome measures heterogeneity. When the number of studies included was considered too small to perform subgroup analyses, the 'best evidence' approach was performed including an analysis of the strength of evidence. 32 Clinical relevance was assessed based on available literature regarding the "Minimally Clinical Important Difference" (MCID). The following MCID's and cutoff scores were used: +3 for the Edmonton Symptom Assessment System (ESAS), 33,34 +1.5 for the Hospital Anxiety and Depression Scale (HADS) or a subscale cutoff of >7 with a minimal 5% difference between study groups, 35 a cutoff of >4 for the Brief Distress Thermometer (BDT) with a minimal 5% difference between study groups, 36 and a minimal change of 50% from baseline score for the Patient Health Questionnaire-9. 37 An MCID or cutoff score for the Symptom Distress Scale (SDS) was not found. Therefore, we applied the rule of half a standard deviation 38,39 as a best proxy leading to an estimated MCID of +3.5. 40
Risk of bias assessment
The Cochrane Collaborations' Risk of bias tool was used to assess risk of bias. 41 Using this tool, seven aspects that may be subject to bias were assessed: 1) random sequence generation, 2) allocation concealment, 3) blinding of participants or personnel, 4) blinding of outcome assessors, 5) incomplete outcome data, 6) selective outcome reporting, and 7) other potential sources of bias including unbalanced groups at baseline. This tool is primarily designed to assess risk of bias in RCTs. For uniformity, we decided to also use this tool in other studies and score RCT-specific aspects as non-applicable.
Risk of bias of included studies was assessed and reported in a standardized spreadsheet by two independent investigators (MES and OPG or MES and AJB). For each category, the risk of bias was assessed as low, high, or unclear. Discrepancies were resolved by consensus and settled through discussion with a third independent investigator (AJB or MYB).
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Results
Search results
The search yielded 4929 titles and was reduced to 3633 titles after removing duplicates.
Of these, 92 titles met the criteria for a full text review. A total of 12 eligible studies, reported in 13 publications, were included: nine randomized controlled trials (RCTs) and three retrospective cohort studies ( Figure 1 ). 25, 42, [51] [52] [53] [43] [44] [45] [46] [47] [48] [49] [50] Three of the RCTs were performed in mixed cancer populations. 42, 43, 50 Comparison of the subsamples of patients with lung cancer vs. the total study samples showed that patients with lung cancer suffered from more distress when compared to the total sample (data not shown). Pooling of results in a meta-analysis was not performed due to intervention-and outcome measures heterogeneity.
Description of interventions
All included studies detailed on a supportive care intervention facilitating SDM as part of the intervention. None of the included studies described the effects of a decision aid. Overall, the goal of such multi-component interventions was to provide earlier and systematic access to palliative care services through either specially trained advanced practice nurses, a registered nurse case manager, or members of a palliative care team. Interventions were primarily aimed at improving emotional well-being and QoL by encouraging selfmanagement, addressing symptom burden, and discussing unmet needs. Table 1 provides further details on the characteristics of the included studies (13 publications).
Measures of distress
Effects on distress are summarized in Table 2 studies measured generic distress using either the ESAS, 42,50 the HADS total score, 44,47 the BDT, 47 or the SDS. 48 Four studies measured anxiety, all using the HADS-A subscale. 25, 44, 46, 49 Five studies measured depression and used either the Center for Epidemiologic studies Depression Scale (CES-D), 42 the Patient Health Questionnaire (PHQ-9), 25, 46, 49 or the HADS-D subscale. 25, 44, 46, 49 Only statistically significant differences are detailed below. Based on the previously described MCID's, clinically relevant differences are displayed in Table 2 .
Effects on distress
Generic distress
None of the five studies measuring generic distress showed statistically significant differences between the intervention group and the usual care group at any time point. 42, 44, 47, 48, 50 
Anxiety
Of the four studies measuring anxiety, one study (n=150) showed a significantly lower percentage of patients with symptoms of anxiety after 12 weeks in the intervention group (17% vs. 27%; p<0.05). 49 Another study (n=151) showed the same trend but there was no significant difference (25% vs. 30%; p=0.66). 25 The other two studies showed no significant differences in mean anxiety scores. 44, 46 Depression Three out of five studies measuring depression observed beneficial effects favoring the intervention group. Two studies (n=151 and n=150) showed a significantly lower proportion of patients with high levels of depression as measured with the HADS-D (16% vs. 38%; p<0.001 and 19% vs. 32%; p<0.001, respectively). 25, 49 These two studies found similar effects
in the PHQ-9 scores (data not shown) as did the third study (n=191): mean depression scores on the PHQ-9 at both 12 weeks (5.61 vs. 7.21; p=0.04) and 24 weeks (5.54 vs. 6.71; p=0.05). 46 The latter study showed no effect in the HADS-D. 46 The two other studies compared mean depression scores and observed no significant differences. 42,44
Measures of healthcare utilization
Effects on healthcare utilization are summarized in Table 3 and the data below are displayed as intervention group (group for which SDM was facilitated) vs. control group.
Eight studies, reported in nine publications and detailing on data from 2914 patients, described effects on healthcare utilization: five RCT's 25,42-45, 48 and three retrospective cohort studies. [51] [52] [53] Across these studies, effects on hospitalizations (n=7), 25,42-45,48,52 emergency department (ED)-visits (n=5), 25,42-45,48 and the use of chemotherapy (n=5) 25,43-45,51,52 were the three most frequently used outcomes and are summarized in detail below. All other outcomes and results related to healthcare utilization are provided in Supplement B.
Hospitalizations
Two of the retrospective studies found evidence for changes with regard to hospitalizations. One of these studies (n=286) compared the percentage of patients that were hospitalized in the last three months before death, across patients receiving early palliative care, late palliative care, or no palliative care (73% vs. 97% vs. 88%; p=0.03). 52 The other study (n=1476) observed that patients who had received a palliative care consultation had a longer mean length of stay (16.3 days vs. 8.3 days; p<0.001). 53 The five RCTs detailing on this showed no significant differences for hospitalizations between intervention and control group. 25, 42, 43, 45, 48 In two of these studies (n=151 and n=223), a trend towards significance,
favoring the intervention groups, was observed in the percentage of hospitalized patients in the last 30 days of life: 37% vs. 54%; no p-value provided, and 47% vs. 56%; p=0. 23. 25,44 Emergency department visits One RCT (n=201) found that the cumulative incidence of patients admitted to the ED was lower in the intervention group (39% vs. 53%; p=0.02). 43 Similar trends, although not significant, were observed in two other RCTs (ED-visits in last 30 days of life: 22% vs. 30%; no p-value provided, and 25% vs. 38%; p=0.09). 25, 44 The remaining two studies did not find differences between the mean number of ED-visits in both study groups. 42,48
Use of chemotherapy
One RCT (n=223) and one retrospective cohort study (n=286, analyzing early palliative care vs. late palliative care vs. no palliative care) reported a significantly lower proportion of patients in the intervention group who received chemotherapy in the last 30 days of life: 12% vs. 26%; p=0.03 and 14% vs. 40% vs. 28%; p=0.003, respectively. 44, 52 Another RCT (n=151)
found similar effects when analyzing the use of chemotherapy in the last 60 days of life (53% vs. 70%; p=0.05) and a trend in the last 30 days of life 30% vs 43%; p=0. 14. 25,45 The other two studies did not observe significant differences in the use of chemotherapy, either as measured by the mean duration of chemotherapy or by the number of chemotherapy treatments. 43,51
Risk of bias
Assessment of the risk of bias of individual studies is shown in Figure 2 . Overall, the risk of selection bias and attrition bias was perceived as low in most RCT's. A high risk of bias was found regarding blinding of participants or personnel, which was not performed in most
studies due to the nature of the interventions. Reporting bias was unclear in some studies since not all study protocols were made publicly available online prior to publication. In two retrospective studies, the study groups were not comparable thereby making selection bias highly likely. 52, 53 In the third retrospective study this was unclear due to scarce information. 51
Discussion
To our knowledge, this is the first systematic review synthesizing evidence on the effects of SDM on distress and healthcare utilization in patients with lung cancer. We identified 12 studies, detailed in 13 publications, describing the effects of supportive care interventions that facilitated SDM as part of their intervention. We found no statistically significant differences in distress in studies using a generic measure. However, mixed effects, in favor of patients for which SDM was facilitated, were found in studies specifically measuring depression or anxiety. Regarding reductions in healthcare utilization, we observed some evidence that SDM leads to reductions in healthcare use.
A number of observations are of importance. As the incorporation of SDM is increasingly propagated for different diseases in order to truly provide patient-centered care, [54] [55] [56] we found evidence that it may lead to less depression and anxiety and reductions in healthcare use. This suggests that involving patients in treatment decisions earlier in the disease course may lead to care that is better aligned with patients' personal preferences and consequently to improved patient-reported outcomes. Yet, since all included studies described multicomponent supportive care interventions, we are not able to deduce whether SDM or other components of these interventions (e.g. earlier referrals or improved symptom management) account for the observed effects. Clearly, palliative care may also improve outcomes related to distress and healthcare utilization without the explicit facilitation of SDM. This is especially relevant since we were unable to measure exactly how and, more importantly, to what extent SDM was provided throughout the included studies.
Unfortunately, we did not identify any studies solely describing the effects of the use of a decision aid for patients with lung cancer. Several relevant pilot studies described the design and pilot testing of such tools. [57] [58] [59] [60] These studies all conclude that facilitating SDM in clinical practice is feasible. Moreover, two of these studies provided preliminary evidence for reductions in distress, enhanced patient satisfaction, better symptom control, and improved disease knowledge and understanding. 59, 60 Such tools have yet to be tested in larger cohorts of patients with (lung) cancer.
We found several research protocols describing interventions aimed at testing the effects of decision aids in patients with different types of (advanced) cancer. [61] [62] [63] [64] Additionally, two recent systematic reviews concluded that the evidence base for SDM is at a relatively early stage. 26, 27 These studies summarized the use of decision aids for patients facing health treatment or screening decisions 26 and patients with a life-limiting illness. 27 Both reviews do provide strong evidence on improved health-literacy and some evidence for reductions in decisional conflict. 26, 27 Strengths of the current review include the use of an extensive, systematic search strategy in five widely used databases from founding date through May 2018. We therefore believe the chance of having missed relevant studies is small. In addition, by limiting our inclusion of eligible studies to patients having received a diagnosis of lung cancer, our results provide important information on a relatively homogeneous patient population. Lastly, we adhered to the evidence-based PRISMA guidelines, thereby improving our study's reporting structure. 28 Several limitations of this review deserve consideration. A number of studies in this review Furthermore, we decided to focus on effects of SDM on distress and healthcare utilization.
We specifically opted for these outcomes since patients with lung cancer are faced with a poor prognosis, are highly distressed, and face difficult treatment choices when approaching the end of life. 65, 66 The observation that subsamples of patients with lung cancer experienced higher levels of distress further supports this notion. Evidently, other outcomes such as quality of life, patient knowledge or patients' decisional satisfaction are also of relevance in this setting. Such outcomes were not included in the current study but should be a target of future studies, especially when SDM is explicitly facilitated through the use of a decision aid.
More work in this context is clearly needed. Development of a MESH term specifically detailing on SDM would be useful in the future. We had to perform a relatively broad search, including 49 terms to fully cover the concept of shared decision making and to ensure that all eligible studies were identified. Further, randomized studies may not be the most optimal mode to study potential benefits of SDM. This could especially be true for patients with lung cancer since the disease course is unpredictable and patients are faced with a poor prognosis.
Yet, despite the relatively small differences, we did find positive effects on emotional outcomes (e.g. anxiety and depression) and healthcare use. In light of the overuse of aggressive therapies near the end of life, 65, 67, 68 OR TI "Treatment decision*" OR TI "decision aid*" OR TI "decision tool*" OR TI "communication aid*" OR TI "decision making" OR TI "decision support" OR TI preference* OR TI "goal* of care" OR TI "patient care planning" OR TI "need* assessment*" OR TI "care need*" OR TI "patient* need*" OR TI "patient participation" OR TI "patient centered care" OR TI "patient centred care" OR TI "advanc* care planning" OR TI "early palliative care" OR TI "integrated care" OR TI "supportive care" OR TI "integrated palliative care" OR AB "Treatment decision*" OR AB "decision aid*" OR AB "decision tool*" OR AB "communication aid*" OR AB "decision making" OR AB "decision support" OR AB preference* OR AB "goal* of care" OR AB "patient care planning" OR AB "need* assessment*" OR AB "care need*" OR AB "patient* need*" OR AB "patient participation" OR AB "patient centered care" OR AB "patient centred care" OR AB "advanc* care planning" OR AB "early palliative care" OR AB "integrated care" OR AB "supportive care" OR AB "integrated palliative care") 
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
5
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
7
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 
Section/topic # Checklist item Reported on page #
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
7
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
9
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
10
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
11
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).
10
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16] ).
12
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
14
Limitations
25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
15
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. For more information, visit: www.prisma-statement.org.
